KR100987360B1 - 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 - Google Patents
원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 Download PDFInfo
- Publication number
- KR100987360B1 KR100987360B1 KR1020047007792A KR20047007792A KR100987360B1 KR 100987360 B1 KR100987360 B1 KR 100987360B1 KR 1020047007792 A KR1020047007792 A KR 1020047007792A KR 20047007792 A KR20047007792 A KR 20047007792A KR 100987360 B1 KR100987360 B1 KR 100987360B1
- Authority
- KR
- South Korea
- Prior art keywords
- adenovirus
- thr
- leu
- ala
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
- C12N2740/17022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
| 혈청의 1/20 으로 중화 |
|||
| 인간 (N=36) |
붉은털 원숭이 (N=52) |
침팬지 (N=20) |
|
| Adhu5 | 9/36 | ND | ND |
| AdC68 | 1/36 | 0/52 | 12/20 |
| Pan 5 | 0/36 | 0/52 | 10/20 |
| Pan 6 | 0/36 | 0/52 | 9/20 |
| Pan 7 | 0/36 | 0/52 | 12/20 |
|
|
109 게놈 카피로 293 세포의 감염 | |||
| 면역화된 토끼로부터 혈청 |
Ad Pan-5 | Ad Pan-6 | Ad Pan-7 | Ad C68 |
| Ad Pan-5 | 1/5120 |
< 1/20 | 1/2560 | 1/2560 |
| Ad Pan-6 | 중화되지 않음 | < 1/20,480 | < 1/20 | < 1/20 |
| Ad Pan-7 | 1/2560 |
1/160 | 1/163,840 | 1/2560 |
| Ad C68 | 중화되지 않음 | < 1/20 | < 1/20 | 1/5120 |
| HuAdS |
AdC7 | |||
| 유전자 | 적정양 (VP ×1012/ml) |
전체 수율 (VP ×1012/ml) |
적정양 (VP ×1012/ml) |
전체 수율 (VP ×1012/ml) |
| Ebowt | 2.6 |
12 | 4.3 | 43 |
| EboS | 4.9 |
49 | 4.6 | 55 |
| EboΔ2 | 2.1 |
9 | 5.8 | 93 |
| EboΔ3 | 1.7 |
8 | 5.3 | 95 |
| EboΔ4 | 3 |
12 | 4.1 | 62 |
| VNA 적정량 | |||
| EboZ 야생형 | EboZs | EboZΔ3 | |
| AdHu5 | 12 | 16 | 12 |
| AdC7 | 44 | 12 | 140 |
Claims (29)
- SEQ ID NO :11의 아미노산 서열을 갖는 AdPan7 헥손 단백질을 포함하는 캡시드를 가지는 재조합체 아데노바이러스에 있어서,상기 아데노바이러스는, E1 유전자의 모두 또는 일부가 결여된 아데노바이러스 서열, 복제와 캡시드화에 필요한 5'와 3' 아데노바이러스 시스-요소, 및 상기 아데노바이러스에 이종인 트랜스유전자로서 숙주 세포에서 상기 트랜스유전자의 발현을 지시하는 서열에 작동가능하게 연결된 트랜스유전자를 더 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- AdPan7 헥손 단백질의 단편을 함유하는 헥손을 포함하는 캡시드, E1 유전자의 모두 또는 일부가 결여된 아데노바이러스 서열, 및 AdPan7에 이종인 핵산 서열을 가지는 재조합체 아데노바이러스에 있어서,상기 AdPan7 헥손 단백질의 단편은, SEQ ID NO :11의 AdPan7 헥손 단백질 서열 길이에서 약 50 아미노산의 N-말단 또는 C-말단이 절단된 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 1 항 또는 제 2 항에 있어서, 상기 캡시드는 SEQ ID NO :20의 AdPan7 섬유 단백질 단편을 더 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 3 항에 있어서, 상기 캡시드는 SEQ ID NO :12의 AdPan7 섬유 단백질을 더 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 1 항 또는 제 2 항에 있어서, 상기 캡시드는 AdPan7 펜톤 단백질을 더 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 1 항 또는 제 2 항에 있어서, 상기 재조합체 아데노바이러스는 복제와 캡시드화에 필요한 5'와 3' 아데노바이러스 시스-요소를 포함하는 의사타입 아데노바이러스이고, 상기 시스-요소는 AdPan7에 이종인 아데노바이러스 유래의 아데노바이러스 5' 역반복된 말단 반복 및 아데노바이러스 3' 역반복된 말단 반복을 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 1 항 또는 제 2 항에 있어서, 상기 재조합체 아데노바이러스는하나 이상의 아데노바이러스 유전자를 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 1 항 또는 제 2 항에 있어서, 상기 아데노바이러스는:Pan7 SEQ ID NO:9 또는 그것에 상보인 서열 중,5' 역반복된 말단 반복(ITR) 서열;E3 ORF1, E3 ORF2, E3 ORF4, E3 ORF5, E3 ORF6, E3 ORF7, E3 ORF8, E3 ORF9로 구성된 군에서 선택된 E3 영역 또는 그것의 단편;E4 ORF7, E4 ORF6, E4 ORF4, E4ORF3, E4 ORF2, E4 ORF1 로 구성된 군에서 선택된 E4 영역 또는 그것의 단편; 및3'ITR로 구성되는 군에서 선택된 아데노바이러스 핵산 서열을 더 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- SEQ ID NO:11의 Pan7 헥손 단백질 및 이종 아데노바이러스 캡시드 단백질 서열을 포함하는 아데노바이러스 캡시드를 가지는 재조합체 아데노바이러스.
- 제 9 항에 있어서, 상기 이종 아데노바이러스 캡시드 단백질 서열은,SEQ ID NO:10의 Pan7 펜톤 단백질 또는 그 단편; 및SEQ ID NO:12의 Pan7 섬유 단백질 또는 그 단편으로부터 선택되는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 9 항 또는 제 10 항에 있어서, 상기 캡시드는 SEQ ID NO:10의 Pan7 펜톤 단백질의 단편을 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 9 항 또는 제 10 항에 있어서, 상기 캡시드는 SEQ ID NO:12의 Pan7 섬유 단백질의 단편을 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- ADPan7 헥손 단백질의 단편을 함유하는 헥손을 포함하는 캡시드와 ADPan7에 이종인 핵산 서열을 가지는 재조합체 아데노바이러스에 있어서,상기 ADPan7 헥손 단백질의 단편은:SEQ ID NO :11의 ADPan7 헥손 단백질 서열의 길이에서 약 50 아미노산의 N-말단 또는 C-말단이 절단된 것;SEQ ID NO :11에 있어서,아미노산 잔기 125 내지 443;아미노산 잔기 138 내지 441;아미노산 잔기 138 내지 163;아미노산 잔기 170 내지 176; 및아미노산 잔기 404 내지 430;으로 구성되는 군으로부터 선택되는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 9 항 또는 제 10 항에 있어서, 상기 아데노바이러스는:Pan7 SEQ ID NO:9 또는 그것에 상보인 서열 중,5' 역반복된 말단 반복(ITR) 서열;E3 ORF1, E3 ORF2, E3 ORF3, E3 ORF4, E3 ORF5, E3 ORF6, E3 ORF7, E3 ORF8, E3 ORF9로 구성된 군으로부터 선택된 E3 영역 또는 그것의 단편;E4 ORF7, E4 ORF6, E4 ORF4, E4ORF3, E4 ORF2, E4 ORF1 로 구성된 군으로부터 선택된 E4 영역 또는 그것의 단편; 및3'ITR로 구성되는 군으로부터 하나 이상 선택된 아데노바이러스 핵산 서열을 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 14 항에 있어서, 상기 아데노바이러스는,SEQ ID NO:10의 Pan7 펜톤 단백질 또는 그 단편; 및SEQ ID NO:12의 Pan7 섬유 단백질 또는 그 단편으로부터 선택되는 적어도 하나의 원숭이 캡시드 단백질을 포함하는 것을 특징으로 하는 재조합체 아데노바이러스.
- 제 1 항 또는 제 2 항에 따르는 재조합체 아데노바이러스를 포함하는 분리된 숙주 세포에 있어서,상기 숙주 세포는 HEK293, HELA 및 A549 세포로 구성된 군으로부터 선택되는 것을 특징으로 하는 분리된 숙주 세포.
- 제 1 항 또는 제 2 항에 따르는 재조합체 아데노바이러스와 약학적으로 허용되는 담체를 포함하는 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33195101P | 2001-11-21 | 2001-11-21 | |
| US60/331,951 | 2001-11-21 | ||
| US36679802P | 2002-03-22 | 2002-03-22 | |
| US60/366,798 | 2002-03-22 | ||
| PCT/US2002/033645 WO2003046124A2 (en) | 2001-11-21 | 2002-11-20 | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040054796A KR20040054796A (ko) | 2004-06-25 |
| KR100987360B1 true KR100987360B1 (ko) | 2010-10-12 |
Family
ID=26987985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047007792A Expired - Fee Related KR100987360B1 (ko) | 2001-11-21 | 2002-11-20 | 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US7247472B2 (ko) |
| EP (4) | EP1453543B1 (ko) |
| JP (9) | JP2005511035A (ko) |
| KR (1) | KR100987360B1 (ko) |
| CN (1) | CN1578678B (ko) |
| AU (1) | AU2002365366B2 (ko) |
| BR (1) | BR0214350A (ko) |
| CA (3) | CA2466431C (ko) |
| CO (1) | CO5590973A2 (ko) |
| HU (3) | HU230365B1 (ko) |
| IL (5) | IL161584A0 (ko) |
| MX (2) | MXPA04004876A (ko) |
| NO (3) | NO332692B1 (ko) |
| NZ (3) | NZ550416A (ko) |
| PH (1) | PH12016500338A1 (ko) |
| PL (1) | PL209133B1 (ko) |
| SG (2) | SG165153A1 (ko) |
| WO (1) | WO2003046124A2 (ko) |
| ZA (1) | ZA200403117B (ko) |
Families Citing this family (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7344872B2 (en) | 2001-06-22 | 2008-03-18 | The Trustees Of The University Of Pennsylvania | Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| KR100987360B1 (ko) | 2001-11-21 | 2010-10-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 |
| EP2277533B1 (en) | 2002-10-23 | 2016-07-20 | GlaxoSmithKline Biologicals S.A. | Methods for vaccinating against malaria |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| ES2478625T3 (es) * | 2003-06-20 | 2014-07-22 | The Trustees Of The University Of Pennsylvania | Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos |
| CA2993042A1 (en) * | 2004-01-23 | 2005-08-04 | Msd Italia S.R.L. | Chimpanzee adenovirus vaccine carriers |
| CA2563538C (en) * | 2004-04-28 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations |
| CA2563500C (en) * | 2004-04-28 | 2016-06-28 | The Trustees Of The University Of Pennsylvania | Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost |
| CA2567741A1 (en) * | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| KR101255870B1 (ko) | 2004-11-16 | 2013-04-17 | 아에라스 글로벌 티비 백신 파운데이션 | 재조합 바이러스 벡터를 포함하는 다가 백신 |
| WO2006094384A1 (en) * | 2005-03-08 | 2006-09-14 | Genesense Technologies Inc. | Use of interleukin 17e for the treatment of cancer |
| GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| DE602007005366D1 (de) * | 2006-04-07 | 2010-04-29 | Chimeros Inc | Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen |
| CN101437538A (zh) * | 2006-04-28 | 2009-05-20 | 宾夕法尼亚州立大学托管会 | 修饰的腺病毒六邻体蛋白和其应用 |
| WO2008027394A2 (en) | 2006-08-28 | 2008-03-06 | The Wistar Institute Of Anatomy And Biology | Constructs for enhancing immune responses |
| CA2896131C (en) | 2007-03-02 | 2020-04-07 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
| AU2008236566A1 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| AU2014203073B2 (en) * | 2007-11-28 | 2016-07-07 | The Trustees Of The University Of Pennsylvania | Simian E adenovirus SAdV-30 |
| CA2707029A1 (en) * | 2007-11-28 | 2009-08-27 | Soumitra Roy | Simian subfamily c adenoviruses sadv-40, -31, and -34 and uses thereof |
| SG186022A1 (en) | 2007-11-28 | 2012-12-28 | Univ Pennsylvania | Simian subfamily b adenovirus sadv-28,27,-29,-32,-33, and -35 and uses thereof |
| KR101662574B1 (ko) * | 2007-11-28 | 2016-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
| WO2009136977A2 (en) | 2008-03-04 | 2009-11-12 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| EP2774985B1 (en) | 2008-10-31 | 2016-12-14 | The Trustees Of The University Of Pennsylvania | Simian adenovirus SAdV-43 and uses thereof |
| WO2010085984A1 (en) * | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| PL2391638T3 (pl) * | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| PT2391638T (pt) * | 2009-02-02 | 2018-10-19 | Glaxosmithkline Biologicals Sa | Sequências de aminoácidos e ácidos nucleicos de adenovírus símio, vetores contendo as mesmas, e as suas utilizações |
| JP2012520663A (ja) | 2009-03-17 | 2012-09-10 | エムディーエックスヘルス エスエー | 遺伝子発現の改良された検出 |
| WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| WO2010138675A1 (en) | 2009-05-29 | 2010-12-02 | The Trustees Of The University Of Pennsylvania | Simian adenovirus 41 and uses thereof |
| WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
| EA201270607A1 (ru) | 2009-11-09 | 2012-09-28 | Генвек, Инк. | Аденовирус обезьян и способы его использования |
| US20130058897A1 (en) | 2010-04-14 | 2013-03-07 | Mogam Biotechnology Research Institute | Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same |
| EP3536781A1 (en) | 2010-04-23 | 2019-09-11 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| US9546369B2 (en) | 2010-04-23 | 2017-01-17 | University Of Massachusetts | Multicistronic expression constructs |
| WO2011133901A2 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
| RS56958B1 (sr) * | 2010-05-14 | 2018-05-31 | Univ Oregon Health & Science | Rekombinantni hcmv i rhcmv vektori i njihova upotreba |
| WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
| WO2012071318A2 (en) | 2010-11-23 | 2012-05-31 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof |
| JP6055779B2 (ja) | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
| WO2012089231A1 (en) * | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| US9267112B2 (en) | 2011-05-10 | 2016-02-23 | The Regents Of The University Of California | Adenovirus isolated from Titi Monkeys |
| US10221218B2 (en) | 2011-05-10 | 2019-03-05 | The Regents Of The University Of California | Adenovirus isolated from titi monkeys |
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
| AU2012305714A1 (en) | 2011-09-09 | 2014-03-27 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
| WO2013036791A2 (en) * | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| TW201318637A (zh) | 2011-09-29 | 2013-05-16 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(一) |
| TW201321016A (zh) | 2011-09-29 | 2013-06-01 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(二) |
| US9629906B2 (en) * | 2011-10-05 | 2017-04-25 | Genvec, Inc. | Affenadenovirus (gorilla) or adenoviral vectors and methods of use |
| KR20140084201A (ko) | 2011-10-19 | 2014-07-04 | 알렉시온 파마 홀딩 | 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법 |
| US9226936B2 (en) | 2011-10-28 | 2016-01-05 | The Wistar of Anatomy and Biology | Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells |
| WO2013082268A1 (en) | 2011-11-30 | 2013-06-06 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for regulation of cell aging, carcinogenesis, and reprogramming |
| CA2873509A1 (en) | 2012-05-18 | 2013-11-21 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
| US9861693B2 (en) | 2012-09-07 | 2018-01-09 | Emory University | HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto |
| WO2014047261A1 (en) * | 2012-09-19 | 2014-03-27 | Beth Israel Deaconess Medical Center, Inc. | Viruses associated with immunodeficiency and enteropathy and methods using same |
| EP2920313B1 (en) * | 2012-11-16 | 2019-06-12 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| CN105189755A (zh) * | 2013-01-15 | 2015-12-23 | 加利福尼亚大学董事会 | 腺病毒及其用途 |
| US9624510B2 (en) | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
| US9402888B2 (en) | 2013-03-14 | 2016-08-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
| MY182168A (en) * | 2013-11-01 | 2021-01-18 | Pfizer | Vectors for expression of prostate-associated antigens |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SI3200815T1 (sl) | 2014-10-02 | 2021-11-30 | The Wistar Institute Of Anatomy And Biology | Postopki in sestavki za zdravljenje raka |
| US10941452B2 (en) | 2014-10-06 | 2021-03-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for isolation of circulating tumor cells (CTC) |
| RU2020140209A (ru) | 2014-10-21 | 2021-01-25 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
| HK1243922A1 (zh) | 2014-11-05 | 2018-07-27 | Voyager Therapeutics, Inc. | 用於治疗帕金森病的aadc多核苷酸 |
| US10570395B2 (en) | 2014-11-14 | 2020-02-25 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| CA2967367C (en) | 2014-11-14 | 2023-05-16 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| WO2016128542A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| EA038402B9 (ru) * | 2015-06-12 | 2021-09-22 | Глаксосмитклайн Байолоджикалс Са | Аденовирусные полинуклеотиды и полипептиды |
| US10983110B2 (en) | 2015-12-02 | 2021-04-20 | Voyager Therapeutics, Inc. | Assays for the detection of AAV neutralizing antibodies |
| EP3416668A4 (en) | 2016-02-18 | 2020-02-19 | The Wistar Institute Of Anatomy And Biology | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| AU2017222568B2 (en) | 2016-02-23 | 2020-09-10 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
| CN117904112A (zh) | 2016-05-18 | 2024-04-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| SG11201809643UA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| SG11201900808SA (en) * | 2016-08-01 | 2019-02-27 | Wistar Inst | Compositions and methods of replication deficient adenoviral vectors for vaccine applications |
| KR20190065251A (ko) | 2016-08-18 | 2019-06-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 모듈러 AAV 전달 시스템을 통한 CRISPR-Cas 게놈 가공 |
| JP2019531787A (ja) | 2016-08-30 | 2019-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| KR20240173209A (ko) | 2016-10-13 | 2024-12-10 | 유니버시티 오브 매사추세츠 | Aav 캡시드 설계 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN110913866A (zh) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
| MX2020001187A (es) | 2017-08-03 | 2020-10-05 | Voyager Therapeutics Inc | Composiciones y métodos para la administración de virus adenoasociados. |
| AU2018338728B2 (en) | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| US11773142B2 (en) | 2017-12-11 | 2023-10-03 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| EP3775175A4 (en) | 2018-04-09 | 2022-02-09 | Salk Institute for Biological Studies | ONCOLYTIC ADENOVIRUS COMPOSITIONS WITH IMPROVED REPLICATION PROPERTIES |
| BR112020023082A2 (pt) | 2018-05-15 | 2021-02-09 | Voyager Therapeutics, Inc. | composições e métodos para o tratamento de doença de parkinson |
| WO2019241486A1 (en) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| WO2020016655A2 (en) | 2018-07-17 | 2020-01-23 | Helixmith Co., Ltd. | Treatment of neuropathy with dna constructs expressing igf-1 isoforms |
| EP3826719A1 (en) | 2018-07-24 | 2021-06-02 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| CA3114621A1 (en) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
| TW202028458A (zh) | 2018-10-05 | 2020-08-01 | 美商航海家醫療公司 | 編碼腺相關病毒(aav)生產蛋白之經基因工程化核酸構築體 |
| EP3867389A1 (en) | 2018-10-15 | 2021-08-25 | Voyager Therapeutics, Inc. | Expression vectors for large-scale production of raav in the baculovirus/sf9 system |
| US20230193315A1 (en) | 2019-01-31 | 2023-06-22 | Oregon Health & Science University | Methods for using transcription-dependent directed evolution of aav capsids |
| CN114269363A (zh) * | 2019-04-17 | 2022-04-01 | 威斯达研究所 | 用于hiv疫苗应用的复制缺陷型腺病毒载体 |
| WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| CN112831524B (zh) * | 2021-02-20 | 2023-06-13 | 苏州相奕生物技术有限公司 | 人工改造的重组腺病毒载体、由其包装的病毒及其应用 |
| AU2022250521A1 (en) | 2021-03-29 | 2023-09-28 | Genematrix Inc. | Recombinant chimeric adenoviral vector substituted by knob gene of chimpanzee adenovirus serotype 6, and application thereof |
| WO2022218997A1 (en) | 2021-04-12 | 2022-10-20 | Centre National De La Recherche Scientifique (Cnrs) | Novel universal vaccine presenting system |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083716A (en) * | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| CA2200869A1 (en) | 1994-10-19 | 1996-05-02 | Bruce C. Trapnell | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
| WO1996013597A2 (en) * | 1994-10-28 | 1996-05-09 | The Trustees Of The University Of Pennsylvania | Improved adenovirus and methods of use thereof |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| AU6261696A (en) * | 1995-06-05 | 1996-12-24 | Trustees Of The University Of Pennsylvania, The | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| US5698202A (en) * | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US5922315A (en) * | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
| US5891994A (en) | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
| CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
| WO1999047691A1 (en) | 1998-03-20 | 1999-09-23 | Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| WO2000011140A1 (en) | 1998-08-20 | 2000-03-02 | The Wistar Institute Of Anatomy And Biology | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| EP1200622A4 (en) | 1999-07-06 | 2004-12-22 | Merck & Co Inc | HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS |
| MXPA02007413A (es) | 2000-01-31 | 2004-07-30 | Smithkline Beecham Biolog | Vacuna para la inmunizacion profilactica o terapeutica contra el vih. |
| US6740525B2 (en) | 2000-02-09 | 2004-05-25 | Genvec, Inc. | Adenoviral capsid containing chimeric protein IX |
| DE60231123D1 (de) | 2001-06-22 | 2009-03-26 | Univ Pennsylvania | Verfahren zur auslösung einer zytotoxischen immunantwort und dafür nützliche rekombinante affen-adenovirus-zusammensetzungen |
| US20040136963A1 (en) | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| US7344872B2 (en) * | 2001-06-22 | 2008-03-18 | The Trustees Of The University Of Pennsylvania | Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
| KR100987360B1 (ko) | 2001-11-21 | 2010-10-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 |
| EP2277533B1 (en) | 2002-10-23 | 2016-07-20 | GlaxoSmithKline Biologicals S.A. | Methods for vaccinating against malaria |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| ES2478625T3 (es) | 2003-06-20 | 2014-07-22 | The Trustees Of The University Of Pennsylvania | Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos |
| CA2563500C (en) | 2004-04-28 | 2016-06-28 | The Trustees Of The University Of Pennsylvania | Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost |
| US20070218536A1 (en) | 2004-04-28 | 2007-09-20 | Guangping Gao | Polyvalent Viral Vectors and a System for Production Thereof |
| CA2563538C (en) | 2004-04-28 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations |
| CA2608316A1 (en) | 2005-05-12 | 2006-11-16 | Glaxo Group Limited | Vaccine composition |
| CN101437538A (zh) * | 2006-04-28 | 2009-05-20 | 宾夕法尼亚州立大学托管会 | 修饰的腺病毒六邻体蛋白和其应用 |
| KR20090092752A (ko) | 2006-07-18 | 2009-09-01 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 말라리아 백신 |
| CA2896131C (en) | 2007-03-02 | 2020-04-07 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
| WO2013055268A1 (en) | 2011-10-13 | 2013-04-18 | Telefonaktiebolaget L M Ericsson (Publ) | Method and node related to channel estimation |
-
2002
- 2002-11-20 KR KR1020047007792A patent/KR100987360B1/ko not_active Expired - Fee Related
- 2002-11-20 US US10/494,364 patent/US7247472B2/en not_active Expired - Fee Related
- 2002-11-20 NZ NZ550416A patent/NZ550416A/en not_active IP Right Cessation
- 2002-11-20 EP EP02803963.4A patent/EP1453543B1/en not_active Expired - Lifetime
- 2002-11-20 SG SG200605559-4A patent/SG165153A1/en unknown
- 2002-11-20 BR BR0214350-0A patent/BR0214350A/pt not_active Application Discontinuation
- 2002-11-20 CA CA2466431A patent/CA2466431C/en not_active Expired - Fee Related
- 2002-11-20 EP EP20100178483 patent/EP2286841A1/en not_active Withdrawn
- 2002-11-20 CA CA2852277A patent/CA2852277C/en not_active Expired - Fee Related
- 2002-11-20 EP EP10178464.3A patent/EP2301582B1/en not_active Expired - Lifetime
- 2002-11-20 JP JP2003547559A patent/JP2005511035A/ja not_active Withdrawn
- 2002-11-20 MX MXPA04004876A patent/MXPA04004876A/es active IP Right Grant
- 2002-11-20 CN CN02823023XA patent/CN1578678B/zh not_active Expired - Fee Related
- 2002-11-20 IL IL16158402A patent/IL161584A0/xx unknown
- 2002-11-20 EP EP16181533.7A patent/EP3108899A1/en not_active Withdrawn
- 2002-11-20 HU HU1300578A patent/HU230365B1/hu not_active IP Right Cessation
- 2002-11-20 CA CA2990322A patent/CA2990322A1/en not_active Abandoned
- 2002-11-20 SG SG2013034475A patent/SG2013034475A/en unknown
- 2002-11-20 WO PCT/US2002/033645 patent/WO2003046124A2/en active Application Filing
- 2002-11-20 HU HU0500987A patent/HU230364B1/hu not_active IP Right Cessation
- 2002-11-20 PL PL373602A patent/PL209133B1/pl unknown
- 2002-11-20 NZ NZ532383A patent/NZ532383A/en not_active IP Right Cessation
- 2002-11-20 MX MX2012000696A patent/MX351516B/es unknown
- 2002-11-20 AU AU2002365366A patent/AU2002365366B2/en not_active Ceased
- 2002-11-20 NZ NZ564586A patent/NZ564586A/en not_active IP Right Cessation
- 2002-11-20 HU HU1400619A patent/HU230488B1/hu not_active IP Right Cessation
-
2004
- 2004-04-22 IL IL161584A patent/IL161584A/en active IP Right Grant
- 2004-04-23 ZA ZA2004/03117A patent/ZA200403117B/en unknown
- 2004-05-26 NO NO20042191A patent/NO332692B1/no not_active IP Right Cessation
- 2004-06-17 CO CO04056841A patent/CO5590973A2/es active IP Right Grant
-
2007
- 2007-06-19 US US11/820,439 patent/US8105574B2/en not_active Expired - Fee Related
-
2009
- 2009-01-29 JP JP2009018231A patent/JP5715749B2/ja not_active Expired - Fee Related
-
2010
- 2010-10-04 JP JP2010225018A patent/JP2011055835A/ja active Pending
-
2011
- 2011-12-27 US US13/337,608 patent/US8603459B2/en not_active Expired - Lifetime
-
2012
- 2012-03-21 NO NO20120337A patent/NO334512B1/no not_active IP Right Cessation
- 2012-11-29 IL IL223344A patent/IL223344A/en active IP Right Grant
-
2013
- 2013-04-30 NO NO20130590A patent/NO335438B1/no not_active IP Right Cessation
- 2013-08-09 JP JP2013167091A patent/JP2013252144A/ja active Pending
- 2013-11-07 US US14/073,979 patent/US9133483B2/en not_active Expired - Fee Related
-
2014
- 2014-01-02 IL IL230292A patent/IL230292A/en active IP Right Grant
- 2014-03-13 IL IL231502A patent/IL231502A/en not_active IP Right Cessation
- 2014-09-10 JP JP2014184006A patent/JP2015057052A/ja not_active Ceased
- 2014-09-10 JP JP2014184003A patent/JP2015057051A/ja not_active Withdrawn
-
2015
- 2015-08-12 US US14/824,336 patent/US20170119873A9/en not_active Abandoned
-
2016
- 2016-02-19 PH PH12016500338A patent/PH12016500338A1/en unknown
- 2016-11-11 JP JP2016220444A patent/JP2017035111A/ja active Pending
- 2016-11-11 JP JP2016220443A patent/JP2017070292A/ja active Pending
- 2016-11-11 JP JP2016220440A patent/JP2017035110A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083716A (en) * | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
Non-Patent Citations (1)
| Title |
|---|
| American Type Culture Collection Catalogue of strain II 4th edition, Viruses and antisera.(1983)* |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100987360B1 (ko) | 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 | |
| US20040136963A1 (en) | Simian adenovirus vectors and methods of use | |
| CN1833027B (zh) | 产生嵌合腺病毒的方法及这种嵌合腺病毒的用途 | |
| AU2017305176B2 (en) | Compositions and methods of replication deficient adenoviral vectors for vaccine applications | |
| ES2627288T3 (es) | Portadores de vacuna de adenovirus de chimpancé | |
| AU2011332025B2 (en) | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof | |
| AU2019271972B2 (en) | Adenovirus polynucleotides and polypeptides | |
| RU2762854C2 (ru) | Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы, и их применения | |
| KR102205908B1 (ko) | 아데노바이러스 벡터 | |
| KR101761691B1 (ko) | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 | |
| KR101761425B1 (ko) | 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도 | |
| CA2528511A1 (en) | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses | |
| CN108135991A (zh) | 新型腺病毒 | |
| CN101213204A (zh) | 丙型肝炎病毒核酸疫苗 | |
| JP7698678B2 (ja) | エプスタインバールウイルス抗原構築物 | |
| KR20200066349A (ko) | 복제 가능 아데노바이러스 벡터 | |
| CN113897388B (zh) | 一种新型黑猩猩腺病毒载体及其构建方法和应用 | |
| NL2023464B1 (en) | Oncolytic Non-human adenoviruses and uses thereof | |
| CN114269363A (zh) | 用于hiv疫苗应用的复制缺陷型腺病毒载体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20130926 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20141006 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20160921 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20181007 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20181007 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |